Skip to main content
. 2020 Nov 27;18(3):251–260. doi: 10.1111/iwj.13524

TABLE 1.

Basic characteristics of the included studies

Study I Case no. I/C (patient no.) Treatment interval/sessions for PRP Treatment interval/sessions for “A” Follow‐up duration Adverse events (cases no. of I/C)
Deng et al 18 EL + PRP 20/20 (40) 1 month/3 Twice a week/24 3 months None
Khattab et al 19 EL + PRP 26/26 (52) 3 weeks/6 Twice a week/32 3 months Pain (6/0), erythema (0/4)
Le 20 EL + PRP 24/60 (84) 1 week/NR Once or twice a week/15 12 months Pain (NR), recurrence (1/13)
Li et al 21 EL + PRP 40/40 (40) 3 weeks/3 Twice a week/18 3 months Pain (40/0), erythema (1/1)
Abdelghani et al 12 FCL + PRP 20/20 (40) 3 weeks/4 Biweekly/4 3 months Erythema (NR)
Kadry et al 22 FCL + PRP 30/30 (30) 2 weeks/6 biweekly/6 3 months Pain (7/10), hyperpigmentation (2/8), erythema (NR)
Mrigpuri et al 23 NCES + PRP 25/25 (20) NA NA 16 weeks None
Parambath et al 24 NCES + PRP 20/20 (20) NA NA 3, 6 months None
Ibrahim et al 13 NB‐UVB + PRP 60/60 (60) 2 weeks/8 Twice a week/16 3 months Pain: 30, ecchymosis: 9
Kale et al 25 NB‐UVB + PRP 32/32 (64) 2 weeks/8 Biweekly/8 2, 4 months Pain: 15/17, ecchymosis: 3/2
El‐Raheem et al 26 Vitamin D + PRP 20/20 (40) 1 month/3 1 month/3 3 months None

Abbreviations: “A”, EL, FCL, NCES, NB‐UVB, or vitamin D; C, control; EL, excimer laser; FCL, fractional carbon dioxide laser; I, intervention; PRP, platelet‐rich plasma; NA, not applicable; NB‐UVB, narrowband‐ultraviolet B; NCES, non‐cultured epidermal cell suspension; NR, not reported.